Compare LZB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | NTLA |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1994 | 2016 |
| Metric | LZB | NTLA |
|---|---|---|
| Price | $32.73 | $13.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 23 |
| Target Price | ★ $39.00 | $20.02 |
| AVG Volume (30 Days) | 588.6K | ★ 3.4M |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | 5.11 | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,349,433,000.00 | $67,671,000.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | $62.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $29.03 | $7.95 |
| 52 Week High | $44.90 | $28.24 |
| Indicator | LZB | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 56.01 |
| Support Level | $31.76 | $11.55 |
| Resistance Level | $39.96 | $15.52 |
| Average True Range (ATR) | 1.22 | 0.61 |
| MACD | -0.96 | 0.24 |
| Stochastic Oscillator | 9.01 | 72.84 |
La-Z-Boy Inc is a world'wide producer of reclining chairs and one of the manufacturers/distributors of residential furniture in the United States. It manufacture, market, import, export, distribute and retail upholstery furniture products. In addition, it import, distribute and retail accessories and casegoods (wood) furniture products. Its reportable operating segments include the Retail segment and the Wholesale segment. Its Retail segment mainly sells upholstered furniture. Wholesale segment manufactures and imports upholstered and casegoods (wood) furniture and sells directly. The company generates majority of revenue from Wholesale segment which manufactures and imports upholstered furniture, such as recliners and motion furniture, sofas, loveseats, chairs, sectionals, modulars, etc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.